Molecules that bind to cd94/nkg2a heterodimer polypeptides
US-2024415889-A1 · Dec 19, 2024 · US
US12460002B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12460002-B2 |
| Application number | US-202017438768-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 27, 2020 |
| Priority date | Mar 29, 2019 |
| Publication date | Nov 4, 2025 |
| Grant date | Nov 4, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to heavy chain variable regions, binding domains and antibodies specific for human CD3, and CD3 binding proteins. The invention further relates to the use of a CD3 binding protein, preferably an antibody, of the invention in the treatment of cancer or autoimmune disease.
Opening claim text (preview).
The invention claimed is: 1 . An antigen-binding protein that binds human CD3 comprising an antibody variable domain comprising a heavy chain variable region and a light chain variable region wherein the heavy chain variable region comprises: a CDR1, CDR2 and CDR3 comprising the amino acid sequence: CDR1: (SEQ ID NO: 42) SFGIS CDR2: (SEQ ID NO: 43) GFIPVLGTANYAQKFQG CDR3: (SEQ ID NO: 44) RGNWNPFDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 51) SKTFTIS; CDR2: (SEQ ID NO: 52) GIIPLFGTITYAQKFQG; CDR3: (SEQ ID NO: 53) RGNWNPFDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 60) SRTFTIS; CDR2: (SEQ ID NO: 61) SIIPIFGTITYAQKFQG; CDR3: (SEQ ID NO: 62) RGNWNPFDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 84) SKTLTIS; CDR2: (SEQ ID NO: 85) GIIPIFGSITYAQKFQD; CDR3: (SEQ ID NO: 86) RGNWNPFDP, or comprising the amino acid sequence: CDR1: (SEQ ID NO: 68) GSGIS; CDR2: (SEQ ID NO: 69) GFIPFFGSANYAQKFRD; CDR3: (SEQ ID NO: 70) RGNWNPLDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 100) GSGIS; CDR2: (SEQ ID NO: 101) GFIPFFGSANYAQKFRD; CDR3: (SEQ ID NO: 102) RGNWNPFDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 199) RFWIG; CDR2: (SEQ ID NO: 200) IIYPGDSDTRYSPSFQG; CDR3:
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Complementarity determining region [CDR] · CPC title
Fab or Fab' · CPC title
Hinge · CPC title
CH3 domain · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.